How were Turning Point Therapeutics' earnings last quarter?

Turning Point Therapeutics, Inc. (NASDAQ:TPTX) released its quarterly earnings results on Tuesday, November, 9th. The company reported ($1.34) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($1.26) by $0.08. The business earned $0.46 million during the quarter. During the same quarter in the prior year, the company posted ($0.42) earnings per share.

What other stocks do shareholders of Turning Point Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Turning Point Therapeutics investors own include NVIDIA (NVDA) , Main Street Capital (MAIN) , OPKO Health (OPK) , Boeing (BA) , General Motors (GM) , AbbVie (ABBV) , Gilead Sciences (GILD) , GSK (GSK) , Johnson & Johnson (JNJ) and Livongo Health (LVGO) .

When did Turning Point Therapeutics IPO?

Turning Point Therapeutics (TPTX) raised $167 million in an initial public offering on Wednesday, April 17th 2019. The company issued 9,300,000 shares at a price of $18.00 per share. Goldman Sachs, SVB Leerink and Wells Fargo Securities served as the underwriters for the IPO and Canaccord Genuity was co-manager.

NASDAQ:TPTX

Turning Point Therapeutics (TPTX) Stock Price, News & Analysis

→ Next President (Not Trump. Not Biden.) (From The Freeport Society) (Ad)

Free TPTX Stock Alerts

Notice: This company has been marked as potentially delisted and may not be actively trading.

Compare

Today's Range: $76.01
▼
$76.01
50-Day Range: $74.80
▼
$76.01
52-Week Range: $23.77
▼
$82.20

Volume: 4,322 shs
Average Volume: 1.14 million shs
Market Capitalization: $3.81 billion

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: N/A

Stock Analysis

Get Turning Point Therapeutics alerts:

Ad The Freeport Society

Next President (Not Trump. Not Biden.)

Do you want to see who I believe will be the next president of the U.S.A? It won't be Biden… And it won't be Trump.

Click here to see why it will be _______________.

About Turning Point Therapeutics Stock (NASDAQ:TPTX)

Turning Point Therapeutics, Inc., a clinical-stage precision oncology biopharmaceutical company, engages in designing and developing therapies that target genetic drivers of cancer. It develops a pipeline of tyrosine kinase inhibitors (TKIs) that targets genetic drivers of cancer in TKI-naïve and TKI-pretreated patients. The company's lead drug candidate repotrectinib is being evaluated in an ongoing Phase 1/2 trial called TRIDENT-1 for the treatment of patients with ROS1+ advanced non-small-cell lung cancer (NSCLC) and patients with ROS1+ and NTRK+ advanced solid tumors. It also develops TPX-0022, a MET/SRC/CSF1R inhibitor, which is in Phase 1 SHIELD-1 clinical trial for patients with advanced solid tumors harboring genetic alterations in MET; TPX-0046, a RET inhibitor that is in 1/2 SWORD-1 clinical trial for patients with advanced solid tumors harboring RET genetic alterations; and TPX-0131, an ALK inhibitor, which is in Phase 1/2 FORGE-1 study for patient with advanced or metastatic TKI-pretreated ALK-positive NSCLC. Turning Point Therapeutics, Inc. was founded in 2013 and is headquartered in San Diego, California.

Ad The Freeport Society

Next President (Not Trump. Not Biden.)

Do you want to see who I believe will be the next president of the U.S.A? It won't be Biden… And it won't be Trump.

Click here to see why it will be _______________.

TPTX Stock News Headlines

February 17, 2024 | wsj.com

Turning Point Brands Inc.

February 12, 2024 | bbc.co.uk

Alzheimer’s: A Turning Point?

April 18, 2024 | The Freeport Society (Ad)

Next President (Not Trump. Not Biden.)

Do you want to see who I believe will be the next president of the U.S.A? It won't be Biden… And it won't be Trump.

February 10, 2024 | investing.com

Turning Point Brands Inc (TPB)

February 10, 2024 | benzinga.com

Cormorant Asset Management, LP's Net Worth

January 15, 2024 | bbc.co.uk

Solving quadratic equations - Edexcel

December 19, 2023 | morningstar.com

COP15: A Turning Point for Investor Approaches to Biodiversity

December 16, 2023 | bbc.com

Turning Point USA: Are conservatives fighting back on campus?

April 18, 2024 | The Freeport Society (Ad)

Next President (Not Trump. Not Biden.)

Do you want to see who I believe will be the next president of the U.S.A? It won't be Biden… And it won't be Trump.

July 29, 2023 | ft.com

Tattoos have reached a turning point at work

July 11, 2023 | newsweek.com

Turning Point USA

June 23, 2023 | health.usnews.com

Turning Point Hospital

June 5, 2023 | bbc.co.uk

Can Vinicius episode be a turning point in football’s racism battle?

May 24, 2023 | usnews.com

Turning Point Secondary School

April 12, 2023 | ca.finance.yahoo.com

2023 could be turning point for office-to-housing conversions: Colliers

March 22, 2023 | theguardian.com

The invasion of Iraq was a turning point on to a path that led towards Ukraine

March 22, 2023 | news.yahoo.com

Putin's arrest warrant is turning point – Zelenskyy

March 22, 2023 | foxnews.com

Zelenskyy: Putin's arrest warrant marks 'turning point,' he’ll be held responsible for 'every destroyed life'

March 21, 2023 | news.yahoo.com

2023 may be turning point in impact of sanctions on Russia

March 21, 2023 | uk.news.yahoo.com

'Deposit return scheme can be turning point in litter battle'

March 19, 2023 | benzinga.com

Turning Point Ministries Welcomes New Chief Development Officer

March 14, 2023 | stocknews.com

1 Stock to Buy This Week and Hold for the Next 20 Years

March 8, 2023 | mirror.co.uk

Harry and Meghan's 'whining' Netflix series was 'turning point' with US, says author

March 1, 2023 | ft.com

Why 2023 might just be a turning point for climate action

February 26, 2023 | mirror.co.uk

Bruno Fernandes outlines Man Utd turning point after "really bad" moment

February 25, 2023 | seekingalpha.com

Turning Point Brands raises dividend by 8% to $0.065

February 19, 2023 | msn.com

These 4 major new Indian military inductions mark a positive turning point

See More Headlines

Receive TPTX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Turning Point Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings: 11/09/2021
Today: 4/18/2024
Fiscal Year End: 12/31/2024

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Sector: Medical
Industry: Pharmaceutical Preparations
Sub-Industry: N/A
Current Symbol: NASDAQ:TPTX
CUSIP: N/A
CIK: 1595893
Web: www.tptherapeutics.com
Phone: (858) 926-5251
Fax: N/A
Employees: 250
Year Founded: N/A

Profitability

EPS (Most Recent Fiscal Year): ($6.90)
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: $-236,550,000.00
Net Margins: N/A
Pretax Margin: -33,959.03%
Return on Equity: -37.45%
Return on Assets: -35.62%

Debt

Debt-to-Equity Ratio: N/A
Current Ratio: 16.83
Quick Ratio: 16.83

Sales & Book Value

Annual Sales: $30.83 million
Price / Sales: 123.46
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: $15.84 per share
Price / Book: 4.80

Miscellaneous

Outstanding Shares: 50,074,000
Free Float: 45,768,000
Market Cap: $3.81 billion
Optionable: Not Optionable
Beta: -0.18

20 Stocks to Sell Now

MarketBeat has just released its list of 20 stocks that Wall Street analysts hate. These companies may appear to have good fundamentals, but top analysts smell something seriously rotten. Are any of these companies lurking around your portfolio? Find out by clicking the link below.

Get This Free Report

Key Executives

Dr. Athena Maria Countouriotis M.D. (Age 50)
Pres, CEO & Director
Comp: $1.19M
Mr. Paolo Tombesi (Age 58)
Exec. VP & CFO
Comp: $741.19k
Dr. Mohammad Hirmand (Age 52)
Exec. VP & Chief Medical Officer
Comp: $783.77k
Mr. Ed Gemo
Sr. VP & Chief Information Officer
Dr. Gavin Hirst Ph.D.
Sr. VP of Chemistry & Interim Chief Scientific Officer
Dr. Adam D. Levy M.B.A.
Ph.D., Sr. VP of Investor Relations & Corp. Communications
Mr. Raymond J. Furey J.D. (Age 54)
Sr. VP & Chief Compliance Officer
Mr. Brian Sun J.D. (Age 38)
M.S., Sr. VP, Gen. Counsel & Corp. Sec.
Ms. Heather Adams
Sr. VP of HR
Dr. Jeffrey P. Whitten
Sr. VP of Pre-Clinical Devel.

Key Competitors

View All Competitors

TPTX Stock Analysis - Frequently Asked Questions

How were Turning Point Therapeutics' earnings last quarter?: Turning Point Therapeutics, Inc. (NASDAQ:TPTX) released its quarterly earnings results on Tuesday, November, 9th. The company reported ($1.34) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($1.26) by $0.08. The business earned $0.46 million during the quarter. During the same quarter in the prior year, the company posted ($0.42) earnings per share.
What other stocks do shareholders of Turning Point Therapeutics own?: Based on aggregate information from My MarketBeat watchlists, some companies that other Turning Point Therapeutics investors own include NVIDIA (NVDA), Main Street Capital (MAIN), OPKO Health (OPK), Boeing (BA), General Motors (GM), AbbVie (ABBV), Gilead Sciences (GILD), GSK (GSK), Johnson & Johnson (JNJ) and Livongo Health (LVGO).
When did Turning Point Therapeutics IPO?: Turning Point Therapeutics (TPTX) raised $167 million in an initial public offering on Wednesday, April 17th 2019. The company issued 9,300,000 shares at a price of $18.00 per share. Goldman Sachs, SVB Leerink and Wells Fargo Securities served as the underwriters for the IPO and Canaccord Genuity was co-manager.

This page (NASDAQ:TPTX) was last updated on 4/18/2024 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial

Turning Point Therapeutics (TPTX) Stock Price, News & Analysis

About Turning Point Therapeutics Stock (NASDAQ:TPTX)

TPTX Stock News Headlines

Company Calendar

Industry, Sector and Symbol

Profitability

Debt

Sales & Book Value

Miscellaneous

Key Executives

Key Competitors

TPTX Stock Analysis - Frequently Asked Questions

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info